Benjamin P. Levy, MD

Articles

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Novel Therapy for NSCLC With ALK Rearrangements

August 9th 2022

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Novel Therapy for NSCLC With KRAS G12C Mutation

August 9th 2022

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

August 2nd 2022

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

August 2nd 2022

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC With EGFR Mutations

July 26th 2022

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Neoadjuvant Strategies in Resectable Non–Small Cell Lung Cancer

July 26th 2022

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS Trials

July 19th 2022

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Adjuvant Osimertinib in Early-Stage NSCLC: The ADAURA Trial

July 19th 2022

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC

July 12th 2022

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Molecular Testing in Advanced-Stage NSCLC: Use of Liquid Biopsy

July 5th 2022

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Use of Molecular Profiling in Early-Stage Non–Small Cell Lung Cancer

July 5th 2022

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

Real-World Data and Barriers to Use of Molecular Testing in NSCLC

June 28th 2022

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Optimal Molecular Testing Practices in Non–Small Cell Lung Cancer

June 28th 2022

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer

February 7th 2022

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

September 20th 2021

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.

Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC

October 28th 2020

Benjamin P. Levy, MD, discusses the mechanism of action of telaglenastat in non–small cell lung cancer.

Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC

September 28th 2020

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

September 25th 2020

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.